Alto Neuroscience, Inc. financial data

Symbol
ANRO on NYSE
Industry
Pharmaceutical Preparations
Location
650 Castro Street, Suite 450, Mountain View, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.79K %
Debt-to-equity 16.7 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27M shares
Common Stock, Shares, Outstanding 27M shares
Weighted Average Number of Shares Outstanding, Basic 27M shares +620%
Weighted Average Number of Shares Outstanding, Diluted 27M shares +620%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.1M USD +63.9%
General and Administrative Expense 5.83M USD +233%
Operating Income (Loss) -18.9M USD -94.3%
Nonoperating Income (Expense) 2.1M USD +264%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -16.8M USD -83.6%
Earnings Per Share, Basic -0.62 USD/shares +74.6%
Earnings Per Share, Diluted -0.62 USD/shares +74.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 182M USD
Other Assets, Current 277K USD
Assets, Current 184M USD
Property, Plant and Equipment, Net 2.35M USD
Operating Lease, Right-of-Use Asset 5.23M USD
Assets 192M USD
Accounts Payable, Current 2.25M USD
Employee-related Liabilities, Current 3.88M USD
Accrued Liabilities, Current 8.23M USD
Liabilities, Current 14M USD
Operating Lease, Liability, Noncurrent 4.62M USD
Liabilities 26.6M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -95K USD
Retained Earnings (Accumulated Deficit) -123M USD
Stockholders' Equity Attributable to Parent 165M USD
Liabilities and Equity 192M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11M USD -46%
Net Cash Provided by (Used in) Financing Activities 135M USD +438%
Net Cash Provided by (Used in) Investing Activities -224K USD -967%
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 27M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 123M USD +607%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 182M USD +255%
Interest Paid, Excluding Capitalized Interest, Operating Activities 248K USD +35.5%
Operating Lease, Liability 5.33M USD
Payments to Acquire Property, Plant, and Equipment 224K USD +967%
Lessee, Operating Lease, Liability, to be Paid 7.14M USD
Operating Lease, Liability, Current 716K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.22M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 917K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.81M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.46M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.5M USD
Operating Lease, Payments 0 USD
Additional Paid in Capital 288M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 200K USD +100%
Share-based Payment Arrangement, Expense 2M USD +269%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares